• Seres Therapeutics scheduled a July 8, 2026 webcast to present top-line results from an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis.
• Results have not yet been presented; the event is positioned as the first public disclosure of the trial’s top-line outcome.
• The study tested whether SER-155 could deliver symptom improvement without the use of immunosuppressive drugs, aiming to avoid disruption of patients’ cancer immunotherapy.
• The trial also assessed safety and tolerability to support evaluation of SER-155 as a potential non-immunosuppressive option for this treatment-limiting complication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.